\(
\def\WIPO{World Intellectual Property Organisation}
\)
Lucence: Lighting up the Future of Cancer Care
2023
格式
| 格式 | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS |
Cite
详细记录
题名
Lucence: Lighting up the Future of Cancer Care
项目类型
Journal article
描述
1 article.
数字对象唯一标识符
摘要
One in three people will get cancer in their lifetime. This stark statistic makes early detection of cancer - when the disease is more treatable and curable - a “must.” A hyper-sensitive blood test developed by Lucence, a precision oncology company based in Singapore and the USA, promises to make early detection a reality. Through its ground-breaking technology, Lucence is working to improve cancer care and cure rates through a simple blood test. Its ultra-sensitive liquid biopsy tests make it possible to profile cancer accurately, rapidly and affordably with a single blood draw, allowing physicians to make better treatment decisions and improve health outcomes. Dr. Min-Han Tan, Founder and CEO of Lucence, talks to WIPO Magazine about his company’s commitment to saving the lives of cancer patients around the world through earlier detection of the disease.
连续资源
出版信息
Geneva, Switzerland : World Intellectual Property Organization, 2023.
语言
eng